Accessibility Statement

Press Releases


Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution

June 21, 2024

Tags |  Product

In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the criteria for disease resolution as




Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products

June 20, 2024

Tags |  Corporate Product

Eli Lilly and Company is committed to meeting the needs of people living with diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases. Today, we are publishing an open lette r to ensure that people living with diabetes and obesity, their




An Open Letter From Eli Lilly and Company Regarding Certain Practices Related to Mounjaro® and Zepbound®

June 20, 2024

Tags |  Corporate Product

Lilly is committed to making life better for people living with diabetes and obesity through developing medicines that change the way healthcare providers can treat these diseases. The development and approvals of Mounjaro ®  and Zepbound ® demonstrate our continued commitment to this mission.




Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks

June 8, 2024

Tags |  Product

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine INDIANAPOLIS , June 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a




Lilly announces departure of Anat Ashkenazi, chief financial officer

June 5, 2024

Tags |  Corporate

INDIANAPOLIS , June 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our board of directors, leadership team and employees, I




Melissa Seymour to join Lilly as executive vice president of Global Quality

June 4, 2024

Tags |  Corporate

INDIANAPOLIS , June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024 .




Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

June 1, 2024

Tags |  Product

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS , June 1, 2024




Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases

May 29, 2024

Tags |  Impact

New   $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India GENEVA , May 29, 2024 /PRNewswire/ -- During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States




Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024

Tags |  Financial

INDIANAPOLIS , May 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 . Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA , will




Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

May 24, 2024

Tags |  Corporate

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe   INDIANAPOLIS , May 24, 2024 /PRNewswire/ -- Eli Lilly and Company